Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Radiotherapy +/- Cisplatin in Head and Neck Cancer
NCT00521521Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2001
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in head and neck cancer (HNC) (2 arms), sponsored by Sanofi. Primary endpoint: Objective Response Rates. Started Jul 2001; status: completed.
02
Drugs
docetaxel
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00521521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521521.